Q BioMed Inc.
QBIO
$0.00
$0.000.00%
OTC PK
| 02/28/2023 | 11/30/2022 | 08/31/2022 | 05/31/2022 | 02/28/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | 12.50K | 26.30K | 170.50K | 75.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 12.50K | 26.30K | 170.50K | 75.10K |
| Cost of Revenue | 2.50K | 80.20K | 66.40K | 72.80K | 73.90K |
| Gross Profit | -2.50K | -67.70K | -40.20K | 97.70K | 1.10K |
| SG&A Expenses | 439.80K | 475.70K | 720.10K | 1.02M | 1.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 445.00K | 578.10K | 807.40K | 1.11M | 1.24M |
| Operating Income | -445.00K | -565.60K | -781.10K | -934.50K | -1.16M |
| Income Before Tax | -721.60K | 2.30M | -795.10K | -1.27M | -2.29M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -721.60K | 2.30M | -795.10K | -1.27M | -2.29M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -721.60K | 2.30M | -795.10K | -1.27M | -2.29M |
| EBIT | -445.00K | -565.60K | -781.10K | -934.50K | -1.16M |
| EBITDA | -432.50K | -553.10K | -768.60K | -922.00K | -1.15M |
| EPS Basic | -0.01 | 0.03 | -0.03 | -0.06 | -0.08 |
| Normalized Basic EPS | 0.00 | 0.02 | -0.01 | -0.02 | -0.04 |
| EPS Diluted | -0.01 | 0.03 | -0.03 | -0.06 | -0.08 |
| Normalized Diluted EPS | 0.00 | 0.02 | -0.01 | -0.02 | -0.04 |
| Average Basic Shares Outstanding | 108.73M | 71.39M | 44.90M | 33.01M | 29.60M |
| Average Diluted Shares Outstanding | 108.73M | 71.39M | 44.90M | 33.01M | 29.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |